#biotechnology #MetaVia #DA-1726

MetaVia Secures $9.3 Million in Public Offering

On January 16, 2026, MetaVia Inc., a Cambridge-based clinical-stage biotechnology company listed on Nasdaq as MTVA, announced the successful closure of its underwritten public offering. This funding round raised approximately $9.3 million, which was facilitated by the full exercise of the underwriter's over-allotment option. The offering was crucial in supporting MetaVia's mission to combat cardiometabolic diseases through advanced therapies.

The offering comprised a combination of Class A and Class B units, totaling about 3,005,574 shares of common stock. Additionally, it included 4,508,361 Series C and Series D warrants, all priced at $3.10 per share. Notably, these warrants empower investors to acquire shares in the future under specific conditions, significantly enhancing the company's capital flexibility.

MetaVia intends to utilize the proceeds for essential working capital and general corporate purposes. Key among these is the continued clinical development of DA-1726, a promising therapy aimed at treating obesity. This innovative drug is an oxyntomodulin (OXM) analogue, designed to activate the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). This dual-action approach not only reduces food intake but also increases energy expenditure, showing superior potential weight loss outcomes compared to existing selective GLP1R agonists.

In a recent Phase 1 clinical trial, DA-1726 showcased its ability to deliver promising results in weight loss and glucose regulation, reaffirming its status as a